Eli Lilly
Lilly pessimistic on 2012 performance
January 6, 2012Sales and Marketing Eli Lilly, lilly, zyprexa
Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic …
Eli Lilly appoints Richard Ascroft as senior director for the ACE region
November 30, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly
Lilly has appointed Richard Ascroft as senior director, corporate affairs, for the Australia, Canada and Europe (ACE) region. His tasks …
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
Lilly Oncology chief resigns
January 27, 2011Research and Development, Sales and Marketing Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing
Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …
Lilly and Boehringer sign major diabetes collaboration
January 12, 2011Research and Development BI10773, Boehringer Ingelheim, Eli Lilly, LY2605541, LY2963016, TGF-beta monoclonal antibody, diabetes, lilly, linagliptin, type II diabetes
Eli Lilly and Boehringer Ingelheim have signed a multi-million dollar collaboration that will see them develop and commercialise a mid- …
Patient deaths halt Lilly cancer trial
December 15, 2010Research and Development Eli Lilly, lilly, melanoma, skin cancer, tasisulam
Lilly has been forced to halt phase III trials of its melanoma candidate tasisulam due to serious safety concerns over …
UK pharma faces rising costs from value-based pricing
December 3, 2010Sales and Marketing Eli Lilly, VBP, lilly, value-based pricing
The government’s planned introduction of a value-based pricing system in the UK could increase costs and bureaucracy for the industry, …
Lilly bolsters diagnostics presence with Avid acquisition
November 9, 2010Research and Development Alzheimer's disease, Alzheimer’s disease, Avid Radiopharma, Eli Lilly, diabetes, emagacestat, florbetapir, lilly
Eli Lilly has acquired specialist diagnostics firm Avid Radiopharma in a deal that will bolster its diagnostics business. Philadelphia-based Avid …
Latest content
Five Facts about cardiovascular disease
